AIDS Therapy
Roche adds MV026048 to its HIV treatment portfolio
Published in AIDS Weekly, June 24th, 2002
A novel nonnucleoside reverse transcriptase inhibitor (nNRTI), MV026048 is currently in preclinical development and is expected to enter phase I clinical studies in 2003.
Current nNRTIs share common resistance profiles, which may reduce the likelihood that a patient will benefit from a second currently approved nNRTI after failing therapy with a first nNRTI. Preclinical data for MV026048 indicate that this new generation compound has a unique resistance profile. A unique resistance profile could make MV026048 a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2002-06-24)
More Articles from AIDS Weekly
- AIDS and HIV Therapy
DC-SIGN could be therapeutic target - Antiviral Cleansing
Plasma treatment appears to be cause of hyperfibrinolysis in transplant recipients - AIDS and HIV Dementia
Cell cycle protein expression altered during HIV encephalitis - AIDS and HIV Therapy
Attenuated infection can create powerful antiviral T cells - AIDS and HIV Therapy
HIV repressor factor linked to viral quiescence - AIDS and HIV Therapy
RNA splicing regulators can be used to modulate viral protein function - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
